Gentian Diagnostics ASA

Regulatory Filings • Sep 24, 2018

PATENT LICENSING AGREEMENT

Moss 24.09.2018

Gentian Diagnostics AS announces today that one of its subsidiaries has entered into an agreement to license out a non-core portfolio of patents to an undisclosed third party. Gentian will receive a lump sum of USD 750,000 to provide a fully paid up global licence for the patents.

The grant of this patent licence is not expected to have any impact on the Company's revenues going forward.

The Company will recognize the revenues from this agreement in the 3rd quarter of 2018.

For further information, please contact:

Njaal Kind CFO, Gentian Diagnostics AS E-mail: njaal.kind@gentian.no Cell Phone: +47 919 06 525

ABOUT GENTIAN DIAGNOSTICS AS:

Gentian Diagnostics AS is a medical diagnostics company listed on Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME".

Gentian is headquartered in Moss, Norway, with a representative office in China and distribution subsidiaries in Sweden and USA.

Gentian designs, develops and markets in vitro diagnostic reagents (IVD) based on its proprietary Nanosense technology. The goal is to offer efficient and accurate reagents for major clinical chemistry platforms with a focus within the areas of kidney disease, cardiac disease, inflammation and veterinary medicine. The Nanosense technology will enable users to move assays from low volume immunology platforms to fully automated, high throughput instruments with shorter turnaround times, better workflow and improved cost efficiency.